Renoprotective properties of L-158809 in type 2 diabetic rat model

段文澜,方京冲,杨秀芳,史虹莉,张志刚,陈广平,郭慕依
DOI: https://doi.org/10.3760/j.issn:1000-6699.2001.06.018
2001-01-01
Abstract:Objective To observe the renoprotective effects of angiotensin Ⅱ (ATⅡ) receptor antagonist, L-158809 and to explore its potential mechanisms. Methods The experimental rats consisted of normal control and type 2 diabetic model groups with or without treatment of L-158809 (2 mg·kg -1 ·d -1 ) for 16 weeks. Blood glucose, HbA 1c , serum immunoreactive insulin, serum creatinine, mean arterial blood pressure, creatinine clearance (Ccr) and urinary albumin excretion index (UAEI) as well as plasma and renal ATⅡ content were measured. The kidney morphological changes were examined by renal histopathology. Marix metalloproteinase-2 (MMP-2) and the tissue inhibitor of metalloproteinase-2 (TIMP-2) expression in renal tissues were studied by immunohistochemistry, zymography and Western blot. Results In type 2 diabetic rats, L-158809 restored the blood pressure (P0.05), Ccr (P0.01) and UAEI (P0.01) to normal level, increased the plasma and renal content of ATⅡmarkedly (P0.001 and P0.01) and alleviated the accumulation of extracellular matrix (ECM) (P0.01). Meanwhile L-158809 enhanced the MMP-2 staining intensity in glomeruli by 2.2 times (P0.01) and improved the gelatinolytic activities of MMP-2 in renal cortex by 85% (P0.01), whereas TIMP-2 staining in glomeruli as well as TIMP-2 content in renal cortex still remained high. Conclusion L-158809 exerts beneficial effects on kidneys of type 2 diabetic rats. Improved ECM turnover and degradation may contribute to the ameliorative effect of L-158809 on the accumulation of ECM in glomeruli.
What problem does this paper attempt to address?